Multidisciplinary Support for Patients with Metastatic Triple-Negative Breast Cancer

This video was supported by Gilead Sciences, Inc., but editorially independently created by the Oncology Nursing News team.

NP Theresa Stukus and NP Nelli Zafman discuss the practical challenges patients with metastatic triple-negative breast cancer (mTNBC) may encounter during prolonged antibody-drug conjugate (ADC) therapy and the critical role of the multidisciplinary care team in supporting long-term treatment success. The faculty highlight common barriers to adherence, including cumulative treatment-related toxicities, work and family responsibilities, caregiver fatigue, transportation challenges, and coordinating specialty appointments such as ophthalmology evaluations. They emphasize that ongoing symptom assessment, timely dose modifications, and proactive supportive care are essential to maintaining quality of life and treatment adherence. The discussion also explores how close collaboration among oncology nurse practitioners, physicians, infusion nurses, pharmacists, social workers, and other healthcare professionals enhances toxicity management, patient education, medication safety, and access to supportive resources. Throughout the conversation, NP Stukus and NP Zafman reinforce that effective communication across the multidisciplinary team is fundamental to delivering comprehensive, patient-centered care and optimizing outcomes for patients with metastatic triple-negative breast cancer.